Cargando…
Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid(®)) in Comparison with Omicron BA.4/5 Bivalent BNT162b2 (Comirnaty(®))
A recombinant SARS-CoV-2 spike protein vaccine (NVX-CoV2373) has been licensed and has a lesser incidence of adverse events. To know the immunological mechanisms of adverse events, the production of cytokines and chemokines was investigated in mice inoculated with NVX-CoV2373. Serum IL-6 was detecte...
Autores principales: | Nakayama, Tetsuo, Ito, Takashi, Ishiyama, Ryoka, Katayama, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675389/ https://www.ncbi.nlm.nih.gov/pubmed/38006009 http://dx.doi.org/10.3390/vaccines11111677 |
Ejemplares similares
-
Myopericarditis following both BNT162b2 and NVX-CoV2373
por: Ahmad, Saima, et al.
Publicado: (2022) -
Serological response to Nuvaxovid (NVX-CoV2373) vaccine given as a fifth dose in non- and low-responder kidney transplant recipients
por: Nowak, Alexandra, et al.
Publicado: (2023) -
Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
por: Bhiman, Jinal N., et al.
Publicado: (2023) -
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
por: Heath, Paul T., et al.
Publicado: (2021) -
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)